首页 > 最新文献

Journal of Heart and Lung Transplantation最新文献

英文 中文
Extrinsic outflow graft obstruction of the HeartMate 3 LVAD: A state-of-the-art review. HeartMate 3 LVAD 的外源性外流移植物阻塞:最新研究综述。
IF 6.4 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-15 DOI: 10.1016/j.healun.2024.07.005
Daniel J Goldstein, Manreet Kanwar, Jennifer Cowger, Snehal Patel, Dan M Meyer, Ezequiel Molina, Christopher Salerno, Ashley Elmer, Sarah Schettle, Jeffrey Teuteberg, Francis Pagani, Josef Stehlik

While notable improvements in survival, the incidence of hemocompatibility-related adverse events, hospitalizations, and cost have been demonstrated with the only commercially available durable left ventricular assist device, a category of pump malfunctions characterized by outflow graft obstruction has been noted with broader use and clinical follow-up of recipients of this technology. Of particular concern is the accumulation of acellular biodebris between the outflow graft and bend relief covering the outflow graft at its origin with the pump (which we term extrinsic outflow graft obstruction at the bend relief). This process tends to be insidious, occurs late in the postoperative course, can be challenging to diagnose, and can result in significant morbidity and mortality. Herein, we provide a review of this complication and outline diagnostic, treatment, and preventive strategies.

虽然唯一的商用耐用左心室辅助装置在存活率、血液相容性相关不良事件发生率、住院率和成本方面都有显著改善,但随着该技术的广泛使用和对受术者的临床随访,我们发现了一类以流出移植物阻塞为特征的泵故障。尤其令人担忧的是,在流出移植物与泵连接处覆盖流出移植物的弯管之间积累了无细胞生物碎屑(我们称之为弯管处的外源性流出移植物阻塞,或 EOGO-BR)。这一过程往往很隐蔽,发生在术后晚期,诊断起来很困难,并可能导致严重的发病率和死亡率。在此,我们将对这一并发症进行回顾,并概述诊断、治疗和预防策略。
{"title":"Extrinsic outflow graft obstruction of the HeartMate 3 LVAD: A state-of-the-art review.","authors":"Daniel J Goldstein, Manreet Kanwar, Jennifer Cowger, Snehal Patel, Dan M Meyer, Ezequiel Molina, Christopher Salerno, Ashley Elmer, Sarah Schettle, Jeffrey Teuteberg, Francis Pagani, Josef Stehlik","doi":"10.1016/j.healun.2024.07.005","DOIUrl":"10.1016/j.healun.2024.07.005","url":null,"abstract":"<p><p>While notable improvements in survival, the incidence of hemocompatibility-related adverse events, hospitalizations, and cost have been demonstrated with the only commercially available durable left ventricular assist device, a category of pump malfunctions characterized by outflow graft obstruction has been noted with broader use and clinical follow-up of recipients of this technology. Of particular concern is the accumulation of acellular biodebris between the outflow graft and bend relief covering the outflow graft at its origin with the pump (which we term extrinsic outflow graft obstruction at the bend relief). This process tends to be insidious, occurs late in the postoperative course, can be challenging to diagnose, and can result in significant morbidity and mortality. Herein, we provide a review of this complication and outline diagnostic, treatment, and preventive strategies.</p>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141633727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term air pollution exposure and the risk of primary graft dysfunction after lung transplantation. 肺移植术后长期暴露于空气污染与原发性移植物功能障碍的风险。
IF 6.4 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-15 DOI: 10.1016/j.healun.2024.07.003
Tatsuki Koyama, Zhiguo Zhao, John R Balmes, Carolyn S Calfee, Michael A Matthay, John P Reilly, Mary K Porteous, Joshua M Diamond, Jason D Christie, Edward Cantu, Lorraine B Ware

Background: Primary graft dysfunction (PGD) contributes substantially to both short- and long-term mortality after lung transplantation, but the mechanisms that lead to PGD are not well understood. Exposure to ambient air pollutants is associated with adverse events during waitlisting for lung transplantation and chronic lung allograft dysfunction, but its association with PGD has not been studied. We hypothesized that long-term exposure of the lung donor and recipient to high levels of ambient air pollutants would increase the risk of PGD in lung transplant recipients.

Methods: Using data from 1428 lung transplant recipients and their donors enrolled in the Lung Transplant Outcomes Group observational cohort study, we evaluated the association between the development of PGD and zip-code-based estimates of long-term exposure to 6 major air pollutants (ozone, nitrogen dioxide, sulfur dioxide, carbon monoxide, particulate matter 2.5, and particulate matter 10) in both the lung donor and the lung recipient. Exposure estimates used daily EPA air pollutant monitoring data and were based on the geographic centroid of each subject's residential zip code. Associations were tested in both univariable and multivariable models controlling for known PGD risk factors.

Results: We did not find strong associations between air pollutant exposures in either the donor or the recipient and PGD.

Conclusions: Exposure to ambient air pollutants, at the levels observed in this study, may not be sufficiently harmful to prime the donor lung or the recipient to develop PGD, particularly when considering the robust associations with other established PGD risk factors.

背景:原发性移植物功能障碍(PGD)是肺移植术后短期和长期死亡率的主要原因,但导致原发性移植物功能障碍的机制尚不十分清楚。暴露于环境空气污染物与肺移植等待期间的不良事件和慢性肺异体移植功能障碍有关,但其与 PGD 的关系尚未得到研究。我们假设,肺供体和受体长期暴露于高浓度的环境空气污染物会增加肺移植受体发生 PGD 的风险:利用肺移植结果组(LTOG)观察性队列研究中 1428 名肺移植受者及其供体的数据,我们评估了肺移植受者和肺供体发生 PGD 与基于邮政编码的六种主要空气污染物(臭氧、二氧化氮、二氧化硫、一氧化碳、PM2.5 和 PM10)长期暴露估计值之间的关系。暴露估计值使用了美国环保署的每日空气污染物监测数据,并以每个受试者居住地的邮政编码中心点为基础。在单变量和多变量模型中测试了与已知 PGD 风险因素的相关性:我们没有发现供体或受体暴露于空气污染物与 PGD 之间有很强的关联:本研究中观察到的环境空气污染物暴露水平可能不足以使供体肺部或受体产生 PGD,特别是考虑到与其他已确定的 PGD 危险因素的密切联系。
{"title":"Long-term air pollution exposure and the risk of primary graft dysfunction after lung transplantation.","authors":"Tatsuki Koyama, Zhiguo Zhao, John R Balmes, Carolyn S Calfee, Michael A Matthay, John P Reilly, Mary K Porteous, Joshua M Diamond, Jason D Christie, Edward Cantu, Lorraine B Ware","doi":"10.1016/j.healun.2024.07.003","DOIUrl":"10.1016/j.healun.2024.07.003","url":null,"abstract":"<p><strong>Background: </strong>Primary graft dysfunction (PGD) contributes substantially to both short- and long-term mortality after lung transplantation, but the mechanisms that lead to PGD are not well understood. Exposure to ambient air pollutants is associated with adverse events during waitlisting for lung transplantation and chronic lung allograft dysfunction, but its association with PGD has not been studied. We hypothesized that long-term exposure of the lung donor and recipient to high levels of ambient air pollutants would increase the risk of PGD in lung transplant recipients.</p><p><strong>Methods: </strong>Using data from 1428 lung transplant recipients and their donors enrolled in the Lung Transplant Outcomes Group observational cohort study, we evaluated the association between the development of PGD and zip-code-based estimates of long-term exposure to 6 major air pollutants (ozone, nitrogen dioxide, sulfur dioxide, carbon monoxide, particulate matter 2.5, and particulate matter 10) in both the lung donor and the lung recipient. Exposure estimates used daily EPA air pollutant monitoring data and were based on the geographic centroid of each subject's residential zip code. Associations were tested in both univariable and multivariable models controlling for known PGD risk factors.</p><p><strong>Results: </strong>We did not find strong associations between air pollutant exposures in either the donor or the recipient and PGD.</p><p><strong>Conclusions: </strong>Exposure to ambient air pollutants, at the levels observed in this study, may not be sufficiently harmful to prime the donor lung or the recipient to develop PGD, particularly when considering the robust associations with other established PGD risk factors.</p>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141633728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recurrent treatment of refractory acute cellular rejection with alemtuzumab after lung transplantation. 用阿来珠单抗治疗肺移植术后复发的难治性急性细胞排斥反应
IF 6.4 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-14 DOI: 10.1016/j.healun.2024.07.004
Eva van Haren, Lukas K van Vugt, Nynke Wijbenga, Heleen van der Sijs, Merel E Hellemons

We present an exceptional case of a lung transplant recipient successfully treated by multiple courses of alemtuzumab for refractory acute cellular rejection (ACR). The patient experienced multiple episodes of ACR following the transplantation procedure. Alemtuzumab was initiated as a third-line rejection treatment and was repeated 6 times. Each treatment course resulted in complete recovery of the pulmonary function and depletion of T- and B-lymphocytes and natural killer cells (NK cells). The onset of rejection was consistently preceded by the recovery of NK cells, while T- and B-lymphocytes remained depleted. This suggests a rejection process mediated by NK cells. This case contributes to recent research findings suggesting that NK cells play a significant role in ACR in lung transplant recipients and stresses the importance to further investigate the role of NK cells in rejection. Furthermore, it demonstrates that ACR following lung transplantation can be repeatedly managed by treatment with alemtuzumab.

我们介绍了一例肺移植受者的特殊病例,患者因难治性急性细胞排斥反应接受了多个疗程的阿仑妥珠单抗治疗,并获得成功。患者在移植手术后经历了多次急性细胞排斥反应。阿来珠单抗被作为三线排斥治疗药物,并重复治疗了六次。每个疗程后,患者的肺功能完全恢复,T淋巴细胞、B淋巴细胞和NK细胞消耗殆尽。排异反应的发生始终先于 NK 细胞的恢复,而 T 淋巴细胞和 B 淋巴细胞仍在消耗。这表明排斥反应过程是由 NK 细胞介导的。最近的研究结果表明,NK细胞在肺移植受者的急性细胞排斥反应中起着重要作用,本病例有助于进一步研究NK细胞在排斥反应中的作用。此外,该病例还表明,肺移植术后的急性细胞排斥反应可通过阿利珠单抗治疗反复控制。数据可用性声明:作者确认文章中提供了支持该研究结果的数据。
{"title":"Recurrent treatment of refractory acute cellular rejection with alemtuzumab after lung transplantation.","authors":"Eva van Haren, Lukas K van Vugt, Nynke Wijbenga, Heleen van der Sijs, Merel E Hellemons","doi":"10.1016/j.healun.2024.07.004","DOIUrl":"10.1016/j.healun.2024.07.004","url":null,"abstract":"<p><p>We present an exceptional case of a lung transplant recipient successfully treated by multiple courses of alemtuzumab for refractory acute cellular rejection (ACR). The patient experienced multiple episodes of ACR following the transplantation procedure. Alemtuzumab was initiated as a third-line rejection treatment and was repeated 6 times. Each treatment course resulted in complete recovery of the pulmonary function and depletion of T- and B-lymphocytes and natural killer cells (NK cells). The onset of rejection was consistently preceded by the recovery of NK cells, while T- and B-lymphocytes remained depleted. This suggests a rejection process mediated by NK cells. This case contributes to recent research findings suggesting that NK cells play a significant role in ACR in lung transplant recipients and stresses the importance to further investigate the role of NK cells in rejection. Furthermore, it demonstrates that ACR following lung transplantation can be repeatedly managed by treatment with alemtuzumab.</p>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Information for Readers 读者信息
IF 6.4 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-11 DOI: 10.1016/S1053-2498(24)01718-2
{"title":"Information for Readers","authors":"","doi":"10.1016/S1053-2498(24)01718-2","DOIUrl":"https://doi.org/10.1016/S1053-2498(24)01718-2","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141594358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Of rivers, recipients and rejection: Revelations from deep immune phenotyping of lung allograft transbronchial biopsy tissue 河流、受体和排斥反应:肺异体移植经支气管活检组织的深度免疫表型揭示。
IF 6.4 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-08 DOI: 10.1016/j.healun.2024.07.001
{"title":"Of rivers, recipients and rejection: Revelations from deep immune phenotyping of lung allograft transbronchial biopsy tissue","authors":"","doi":"10.1016/j.healun.2024.07.001","DOIUrl":"10.1016/j.healun.2024.07.001","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1053249824017315/pdfft?md5=7171635db5a81e070571c8ba264628be&pid=1-s2.0-S1053249824017315-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141579870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Balloon pulmonary angioplasty: Not quite the fountain of youth in chronic thromboembolic pulmonary hypertension 球囊肺血管成形术:慢性血栓栓塞性肺动脉高压的青春之泉。
IF 6.4 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-05 DOI: 10.1016/j.healun.2024.06.016
{"title":"Balloon pulmonary angioplasty: Not quite the fountain of youth in chronic thromboembolic pulmonary hypertension","authors":"","doi":"10.1016/j.healun.2024.06.016","DOIUrl":"10.1016/j.healun.2024.06.016","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141554959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pediatric lung transplantation: A new landscape following the height of the COVID-19 pandemic 小儿肺移植:COVID-19大流行后的新局面。
IF 6.4 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-01 DOI: 10.1016/j.healun.2024.06.017
{"title":"Pediatric lung transplantation: A new landscape following the height of the COVID-19 pandemic","authors":"","doi":"10.1016/j.healun.2024.06.017","DOIUrl":"10.1016/j.healun.2024.06.017","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141498213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of cardiac allograft vasculopathy incidence between simultaneous multiorgan and isolated heart transplant recipients in the United States 美国同时接受多器官和单独接受心脏移植者的心脏移植血管病发病率比较。
IF 6.4 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-06-29 DOI: 10.1016/j.healun.2024.06.014

Background

Prior studies have shown reduced development of cardiac allograft vasculopathy (CAV) in multiorgan transplant recipients. The aim of this study was to compare the incidence of CAV between isolated heart transplants and simultaneous multiorgan heart transplants in the contemporary era.

Methods

We utilized the Scientific Registry of Transplant Recipients to perform a retrospective analysis of first-time adult heart transplant recipients between January 1, 2010 and December 31, 2019 in the United States. The primary end-point was the development of angiographic CAV within 5 years of follow-up.

Results

Among 20,591 patients included in the analysis, 1,279 (6%) underwent multiorgan heart transplantation (70% heart-kidney, 16% heart-liver, 13% heart-lung, and 1% triple-organ), and 19,312 (94%) were isolated heart transplant recipients. The average age was 53 years, and 74% were male. There were no significant between-group differences in cold ischemic time. The incidence of acute rejection during the first year after transplant was significantly lower in the multiorgan group (18% vs 33%, p < 0.01). The 5-year incidence of CAV was 33% in the isolated heart group and 27% in the multiorgan group (p < 0.0001); differences in CAV incidence were seen as early as 1 year after transplant and persisted over time. In multivariable analysis, multiorgan heart transplant recipients had a significantly lower likelihood of CAV at 5 years (hazard ratio = 0.76, 95% confidence interval: 0.66-0.88, p < 0.01).

Conclusions

Simultaneous multiorgan heart transplantation is associated with a significantly lower long-term risk of angiographic CAV compared with isolated heart transplantation in the contemporary era.

背景:先前的研究表明,多器官移植受者的心脏移植物血管病(CAV)发病率较低。本研究的目的是比较当代孤立心脏移植和同时进行多器官心脏移植的 CAV 发生率:我们利用移植受者科学登记处对 2010 年 1 月 1 日至 2019 年 12 月 31 日期间美国首次接受心脏移植的成人受者进行了回顾性分析。主要终点是随访5年内出现血管造影CAV:在纳入分析的20591名患者中,1279人(6%)接受了多器官心脏移植(70%为心-肾、16%为心-肝、13%为心-肺、1%为三器官),19312人(94%)为孤立心脏移植受者。平均年龄为 53 岁,74% 为男性。各组间的低温缺血时间无明显差异。多器官移植组在移植后第一年内急性排斥反应的发生率明显较低(18% 对 33%,P结论:在当代,同时进行多器官心脏移植与孤立心脏移植相比,血管造影CAV的长期风险明显较低。
{"title":"Comparison of cardiac allograft vasculopathy incidence between simultaneous multiorgan and isolated heart transplant recipients in the United States","authors":"","doi":"10.1016/j.healun.2024.06.014","DOIUrl":"10.1016/j.healun.2024.06.014","url":null,"abstract":"<div><h3>Background</h3><p>Prior studies have shown reduced development of cardiac allograft vasculopathy (CAV) in multiorgan transplant recipients. The aim of this study was to compare the incidence of CAV between isolated heart transplants and simultaneous multiorgan heart transplants in the contemporary era.</p></div><div><h3>Methods</h3><p>We utilized the Scientific Registry of Transplant Recipients to perform a retrospective analysis of first-time adult heart transplant recipients between January 1, 2010 and December 31, 2019 in the United States. The primary end-point was the development of angiographic CAV within 5 years of follow-up.</p></div><div><h3>Results</h3><p>Among 20,591 patients included in the analysis, 1,279 (6%) underwent multiorgan heart transplantation (70% heart-kidney, 16% heart-liver, 13% heart-lung, and 1% triple-organ), and 19,312 (94%) were isolated heart transplant recipients. The average age was 53 years, and 74% were male. There were no significant between-group differences in cold ischemic time. The incidence of acute rejection during the first year after transplant was significantly lower in the multiorgan group (18% vs 33%, <em>p</em> &lt; 0.01). The 5-year incidence of CAV was 33% in the isolated heart group and 27% in the multiorgan group (<em>p</em> &lt; 0.0001); differences in CAV incidence were seen as early as 1 year after transplant and persisted over time. In multivariable analysis, multiorgan heart transplant recipients had a significantly lower likelihood of CAV at 5 years (hazard ratio = 0.76, 95% confidence interval: 0.66-0.88, <em>p</em> &lt; 0.01).</p></div><div><h3>Conclusions</h3><p>Simultaneous multiorgan heart transplantation is associated with a significantly lower long-term risk of angiographic CAV compared with isolated heart transplantation in the contemporary era.</p></div>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1053249824017066/pdfft?md5=1b8cc9374d7670161d737d42997e2340&pid=1-s2.0-S1053249824017066-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141476739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A comprehensive, multifaceted strategy to increase pediatric donor heart utilization 提高小儿捐献心脏利用率的综合、多方面战略。
IF 6.4 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-06-28 DOI: 10.1016/j.healun.2024.06.015

Background

In 2016, we initiated a quality improvement endeavor to increase pediatric heart offer acceptance. This study assessed the effect of these interventions at our center.

Methods

We evaluted pre- and postimplementation cohorts (January 1, 2008-December 31, 2016 vs January 1, 2017-July 1, 2023) comparing donor heart utilization. Six interventions were iterated over time to increase offer acceptance (“extended criteria”): ABO-incompatible transplant, ex vivo perfusion for distanced donors, 3-dimensional total cardiac volume (TCV) assessment, acceptance of hepatitis-C or Severe Acute Respiratory Syndrome Coronavirus 2 infected donors, and institutional culture change favoring consideration of donors previously considered unacceptable. Outcomes studied included annual HT volume, median waitlist duration, sequence number at acceptance, and post-transplant clinical outcomes.

Results

During the study period, annual transplant volume increased from 16/year to 25/year pre- and postimplementation. Three hundred thirteen of 389 (80%) listed patients were transplanted. Waitlist duration shortened postimplementation (p = 0.01), as did the percentage of accepted heart offers utilizing at least 1 extended criterion (p < 0.001). Institutional culture change and TCV assessment had the largest impact on donor heart utilization (p = 0.04 and p < 0.001). There was no difference in post-HT intubation or intensive care unit days (p = 0.05-0.9), though post-transplant hospitalization duration (p < 0.001) increased. Post-transplant survival was unaffected by the use of extended criteria hearts (p = 0.3).

Conclusions

We report a successful longitudinal, multifaceted effort to increase organ offer utilization, with institutional culture change and TCV assessments most impactful. The use of extended criteria hearts was not associated with inferior survival.

背景:许多提供给儿科心脏移植(HT)的心脏都没有得到安置。2016 年,我们启动了一项质量改进工作,以提高心脏接受率。本研究评估了这些干预措施在我们中心的效果:评估实施前后队列(1/1/2008-12/31/2016 vs. 1/1/2017- 7/1/2023),比较供体心脏利用率。随着时间的推移,对六项干预措施进行了迭代,以提高接受度("扩展标准"):ABO不相容移植、对距离较远的捐献者进行体外灌注、三维心脏总容积(TCV)评估、接受丙型肝炎或SARS-COV-2感染的捐献者,以及改变机构文化,倾向于考虑以前被认为不可接受的捐献者(公共卫生服务风险、心肺复苏持续时间长等)。研究结果包括年移植量、中位等待时间、接受时的序列号以及移植后的临床结果:结果:从 2008 年 1 月至 2023 年 7 月,年移植量从实施前后的 16/ 年增加到 25/ 年。有 313/389 名(80%)列入名单的患者接受了移植。实施后,等待名单的持续时间缩短了(P=0.01),接受至少一项扩展标准的心脏供体的百分比也缩短了(PC结论:我们报告了通过纵向、多方面的努力提高器官利用率所带来的心脏捐献接受率的提高,其中机构文化变革和 TCV 评估的影响最大。使用扩展标准心脏与存活率较低无关。
{"title":"A comprehensive, multifaceted strategy to increase pediatric donor heart utilization","authors":"","doi":"10.1016/j.healun.2024.06.015","DOIUrl":"10.1016/j.healun.2024.06.015","url":null,"abstract":"<div><h3>Background</h3><p>In 2016, we initiated a quality improvement endeavor to increase pediatric heart offer acceptance. This study assessed the effect of these interventions at our center.</p></div><div><h3>Methods</h3><p><span>We evaluted pre- and postimplementation cohorts (January 1, 2008-December 31, 2016 vs January 1, 2017-July 1, 2023) comparing donor heart utilization. Six interventions were iterated over time to increase offer acceptance (“extended criteria”): ABO-incompatible transplant, ex vivo perfusion for distanced donors, 3-dimensional total </span>cardiac volume<span> (TCV) assessment, acceptance of hepatitis-C or Severe Acute Respiratory Syndrome Coronavirus 2<span> infected donors, and institutional culture change favoring consideration of donors previously considered unacceptable. Outcomes studied included annual HT volume, median waitlist duration, sequence number at acceptance, and post-transplant clinical outcomes.</span></span></p></div><div><h3>Results</h3><p>During the study period, annual transplant volume increased from 16/year to 25/year pre- and postimplementation. Three hundred thirteen of 389 (80%) listed patients were transplanted. Waitlist duration shortened postimplementation (<em>p</em> = 0.01), as did the percentage of accepted heart offers utilizing at least 1 extended criterion (<em>p</em> &lt; 0.001). Institutional culture change and TCV assessment had the largest impact on donor heart utilization (<em>p</em> = 0.04 and <em>p</em><span> &lt; 0.001). There was no difference in post-HT intubation<span> or intensive care unit days (</span></span><em>p</em> = 0.05-0.9), though post-transplant hospitalization duration (<em>p</em> &lt; 0.001) increased. Post-transplant survival was unaffected by the use of extended criteria hearts (<em>p</em> = 0.3).</p></div><div><h3>Conclusions</h3><p>We report a successful longitudinal, multifaceted effort to increase organ offer utilization, with institutional culture change and TCV assessments most impactful. The use of extended criteria hearts was not associated with inferior survival.</p></div>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141468554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-time lung weight measurement during clinical ex vivo lung perfusion. 在临床体外肺灌注过程中实时测量肺重量。
IF 6.4 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-06-27 DOI: 10.1016/j.healun.2024.06.013
Ichiro Sakanoue, Toshihiro Okamoto, Kamal S Ayyat, James J Yun, Abdel Moneim Tantawi, Kenneth R McCurry

Background: Real-time lung weight (LW) measurement is a simple and noninvasive technique for detecting extravascular lung water during ex vivo lung perfusion (EVLP). We investigated the feasibility of real-time LW measurement in clinical EVLP as a predictor of transplant suitability and post-transplant outcomes.

Methods: In our clinical acellular EVLP protocol, real-time LW was measured in 117 EVLP cases from June 2019 to June 2022. The estimated LW gain at each time point was calculated using a scale placed under the organ chamber. The lungs were classified into 4 categories based on LW adjusted for height and compared between suitable and unsuitable cases. The relationship between estimated LW gain and primary graft dysfunction was also investigated.

Results: The estimated LW gain during the EVLP significantly correlated with the LW gain (post-EVLP LW and pre-EVLP LW) measured on the back table (R2 = 0.61, p < 0.01). In the adjusted LW categories 2 to 4, the estimated LW gain at 0-1 hour after EVLP was significantly higher in unsuitable cases than in suitable cases. The area under the curve for the estimated LW gain was ≥0.80. Primary graft dysfunction grades 0 to 1 had a significantly lower estimated LW gain at 60 minutes than grades 2 to 3 (-43 vs 1 g, p < 0.01).

Conclusions: Real-time lung measurements can predict transplant suitability and post-transplant outcomes by the early detection of extravascular lung water during the initial 1 hour of EVLP.

背景:实时肺重量(LW)测量是一种在体外肺灌注(EVLP)过程中检测血管外肺水分的简单无创技术。我们研究了在临床 EVLP 中实时测量肺重量作为移植适宜性和移植后预后预测指标的可行性:在我们的临床无细胞 EVLP 方案中,从 2019 年 6 月到 2022 年 6 月对 117 例 EVLP 进行了实时 LW 测量。使用放置在器官腔下的刻度计算每个时间点的估计LW增量。根据按身高调整后的肺活量将肺分为四类,并对适合和不适合的病例进行比较。此外,还研究了估计肺活量增加与原发性移植物功能障碍之间的关系:结果:EVLP期间估计的肺活量增加与在后台上测量的肺活量增加(EVLP后肺活量-EVLP前肺活量)显著相关(R2=0.61,PC结论:通过在EVLP最初1小时内早期检测血管外肺水,实时肺测量可预测移植适宜性和移植后预后。
{"title":"Real-time lung weight measurement during clinical ex vivo lung perfusion.","authors":"Ichiro Sakanoue, Toshihiro Okamoto, Kamal S Ayyat, James J Yun, Abdel Moneim Tantawi, Kenneth R McCurry","doi":"10.1016/j.healun.2024.06.013","DOIUrl":"10.1016/j.healun.2024.06.013","url":null,"abstract":"<p><strong>Background: </strong>Real-time lung weight (LW) measurement is a simple and noninvasive technique for detecting extravascular lung water during ex vivo lung perfusion (EVLP). We investigated the feasibility of real-time LW measurement in clinical EVLP as a predictor of transplant suitability and post-transplant outcomes.</p><p><strong>Methods: </strong>In our clinical acellular EVLP protocol, real-time LW was measured in 117 EVLP cases from June 2019 to June 2022. The estimated LW gain at each time point was calculated using a scale placed under the organ chamber. The lungs were classified into 4 categories based on LW adjusted for height and compared between suitable and unsuitable cases. The relationship between estimated LW gain and primary graft dysfunction was also investigated.</p><p><strong>Results: </strong>The estimated LW gain during the EVLP significantly correlated with the LW gain (post-EVLP LW and pre-EVLP LW) measured on the back table (R<sup>2</sup> = 0.61, p < 0.01). In the adjusted LW categories 2 to 4, the estimated LW gain at 0-1 hour after EVLP was significantly higher in unsuitable cases than in suitable cases. The area under the curve for the estimated LW gain was ≥0.80. Primary graft dysfunction grades 0 to 1 had a significantly lower estimated LW gain at 60 minutes than grades 2 to 3 (-43 vs 1 g, p < 0.01).</p><p><strong>Conclusions: </strong>Real-time lung measurements can predict transplant suitability and post-transplant outcomes by the early detection of extravascular lung water during the initial 1 hour of EVLP.</p>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":null,"pages":null},"PeriodicalIF":6.4,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141468556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Heart and Lung Transplantation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1